CAR T-cell therapy in autoimmune diseases: where are we and ...
Under the strong selective pressure of CD19 CAR T cells, mutations or deletions of the CD19 gene can occur, leading to the silencing of CD19 gene expression. 70 Strategies to overcome …
Prizloncabtagene autoleucel: a new CAR T cell for B-NHL
2 天之前 · Anti-CD19 CAR T-cell failure is associated with a grim median survival of just 6 months. 6 Furthermore, few of these patients are eligible for additional treatments, with an …
CD19-targeted CAR T-cell therapeutics for hematologic ...
2016年6月30日 · Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B …
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case …
2024年2月21日 · We evaluated 15 patients with severe SLE (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single infusion of CD19 …
Single-Center Experience Highlights Utility of CD19-Directed ...
1 天前 · CD19-directed CAR T-cell therapy showed manageable toxicities, with cytokine release syndrome in 95% of patients, mostly grade 1 or 2. Neurotoxicity occurred in 9% of patients, …
CD19 CAR T-Cell Therapy in Autoimmune Disease - PubMed
2024年2月22日 · Methods: We evaluated 15 patients with severe SLE (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single …
TET2 downregulation enhances the antitumor efficacy of CD19 ...
2025年2月26日 · Chimeric antigen receptor (CAR) T cells have demonstrated remarkable clinical efficacy in patients with hematologic malignancies [].However, long-term follow-up studies of …